Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
120.43
+4.72 (4.08%)
At close: May 12, 2025, 4:00 PM
118.51
-1.92 (-1.59%)
After-hours: May 12, 2025, 7:15 PM EDT
Neurocrine Biosciences Stock Forecast
Stock Price Forecast
The 20 analysts with 12-month price forecasts for Neurocrine Biosciences stock have an average target of 163.2, with a low estimate of 115 and a high estimate of 219. The average target predicts an increase of 35.51% from the current stock price of 120.43.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Neurocrine Biosciences stock from 20 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 6 | 6 | 7 | 7 |
| Buy | 11 | 11 | 11 | 11 | 11 | 11 |
| Hold | 5 | 5 | 4 | 4 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 22 | 21 | 21 | 21 | 20 | 20 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Reiterates $160 → $154 | Buy | Reiterates | $160 → $154 | +27.88% | May 6, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $137 → $145 | Buy | Maintains | $137 → $145 | +20.40% | May 6, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $155 → $165 | Strong Buy | Maintains | $155 → $165 | +37.01% | May 6, 2025 |
| BMO Capital | BMO Capital | Hold Maintains $96 → $115 | Hold | Maintains | $96 → $115 | -4.51% | May 6, 2025 |
| UBS | UBS | Strong Buy Maintains $137 → $152 | Strong Buy | Maintains | $137 → $152 | +26.21% | May 6, 2025 |
Financial Forecast
Revenue This Year
2.72B
from 2.36B
Increased by 15.36%
Revenue Next Year
3.16B
from 2.72B
Increased by 16.34%
EPS This Year
4.19
from 3.29
Increased by 27.36%
EPS Next Year
6.45
from 4.19
Increased by 54.01%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.9B | 3.5B | 4.4B | ||
| Avg | 2.7B | 3.2B | 3.6B | ||
| Low | 2.5B | 2.8B | 3.1B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 22.9% | 30.6% | 38.6% | ||
| Avg | 15.4% | 16.3% | 14.3% | ||
| Low | 7.0% | 2.3% | -1.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 6.46 | 9.64 | 14.84 | ||
| Avg | 4.19 | 6.45 | 9.16 | ||
| Low | 2.49 | 3.60 | 3.08 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 96.3% | 130.0% | 129.9% | ||
| Avg | 27.4% | 54.0% | 42.0% | ||
| Low | -24.3% | -14.2% | -52.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.